Program Book - Confex

Abstract Moderator disclosure
A
Anolik, Jennifer H, MD, PhD
B-cell Biology and Targets in Autoimmune
Disease
Disclosure: MedImmune, 5; UCB, 5
Systemic Lupus Erythematosus - Clinical
Aspects: Translational Studies
Disclosure: MedImmune, 5; UCB, 5
Aranow, C., MD
Systemic Lupus Erythematosus - Clinical
Aspects: New Therapies
Disclosure: Amgen, 2; Cephalon, 2; Eli Lilly and
Company, 2; Genentech and Biogen IDEC Inc, 2;
GlaxoSmithKline, 5; Human Genome Sciences,
Inc, 2; Medimmune, 5; UCB, 2
Aringer, Martin, MD
Rheumatoid Arthritis Treatment - Small
Molecules, Biologics, Therapy: Biomarkers
Disclosure: GlaxoSmithKline, 5; Novartis
Pharmaceutical Corporation, 5; Roche
Pharmaceuticals, 5
B
Baker, Nancy A, ScD, MPH, OTR/L
ARHP Research Methodology
Disclosure: Nothing to Disclose
Baron, Murray, MD
Systemic Sclerosis Fibrosing Syndromes and
Raynaud’s - Clinical Aspects and Therapeutics II
Disclosure: Nothing to Disclose
Bathon, Joan M., MD
Rheumatoid Arthritis Treatment - Small
Molecules, Biologics, Therapy: Existing Biologics
Disclosure: Nothing to Disclose
Becker, Michael A., MD
Metabolic and Crystal Arthropathies II: Anti-
Gout Medications – Dosing, Adverse Effects, and
Economic Burden
Disclosure: Takeda, Savient, BioCryst, Ardea,
Metabolex, URL/Mutual, Regeneron, Menarini,
Teijin, Chugai, 5
Bernatsky, Sasha, MD, PhD
Systemic Lupus Erythematosus - Clinical
Aspects: Cardiac Disease/Organ Damage
Disclosure: Nothing to Disclose
Bilek, Laura D., PhD, PT
ARHP Education and Community Programs
Disclosure: Nothing to Disclose
Bingham III, Clifton O., MD
Rheumatoid Arthritis Treatment - Small
Molecules, Biologics, Therapy: Existing Diseasemodifying
Antirheumatic Drugs - Tight Control,
Induction and Drug Withdrawal Trials
Disclosure: Amgen, BMS, Centocor, Genetech/
Roche, Millenium, Pfizer, UCB, 5; BMS,
Genentech/Roche, Biogen/IDEC, UCB, 2
Blitz, Jill R., PT, DPT
ARHP Rehabilitation Science
Disclosure: Nothing to Disclose
Boackle, Susan A., MD
Innate Immunity and Rheumatic Disease
Disclosure: Nothing to Disclose
Bongartz, Tim, MD, MS
Epidemiology and Health Services Research V:
Drugs
Disclosure: Nothing to Disclose
Boumpas, Dimitrios T., MD
Systemic Lupus Erythematosus - Clinical
Aspects: Renal
Disclosure: Nothing to Disclose
Bradley, David S., PhD
Rheumatoid Arthritis - Animal Models I
Disclosure: Nothing to Disclose
Bykerk, Vivian, MD
Rheumatoid Arthritis Treatment - Small
Molecules, Biologics, Therapy: Novel
Compounds I
Disclosure: Novartis Pharmaceutical
Corporation, 1
C
Carrino, John, MD, MPH
Imaging of Rheumatic Disease II: X-ray,
Computed Tomography and Magnetic
Resonance Imaging
Disclosure: Carestream, 2; Medtronic, 5; Quality
Medical Metrics, 5; Siemens, 2; Toshiba, 2
Chatham, W. Winn, MD
Miscellaneous Rheumatic and Inflammatory
Diseases
Disclosure: Human Genome Sciences,
GlaxoSmithKline, 2
Chohan, Saima, MD
Metabolic and Crystal Arthropathies II: Anti-
Gout Medications – Dosing, Adverse Effects, and
Economic Burden
Disclosure: Nothing to Disclose
Choi, Hyon, MD, PhD
Epidemiology and Health Services Research I:
Gout
Disclosure: Centocor, Inc, 9; Novartis
Pharmaceutical Corporation, 5; Takeda, 2; URL,
2
Chu, Cong-Qiu, MD, PhD
ARHP Clinical Practice/Patient Care II
Disclosure: Bristol-Myers Squibb, 8; Covidien, 8
Cimaz, Rolando, MD
ACR/ARHP Combined Pediatrics Abstract
Session
Disclosure: Nothing to Disclose
Clauw, Daniel J., MD
Fibromyalgia and Soft Tissue Disorders II
Disclosure: Cypress Biosciences, Inc, 5; Forest
Laboratories, 2, 5; Jazz, 5; Johnson & Johnson,
5; Lilly, 5; Merck Pharmaceuticals, 2; Nuvo, 5;
Pfizer Inc, 2, 5
Clegg, Daniel O., MD
Spondylarthropathies and Psoriatic Arthritis -
Clinical Aspects and Treatment II
Disclosure: Nothing to Disclose
Cohen, Stanley B., MD
Rheumatoid Arthritis Treatment - Small
Molecules, Biologics, Therapy: Novel
Compounds II
Disclosure: none, 5
Corr, Maripat, MD
Rheumatoid Arthritis - Human Etiology and
Pathogenesis II: Pathogenesis of Rheumatoid
Arthritis - What’s New
Disclosure: Nothing to Disclose
Costenbader, Karen H., MD, MPH
Epidemiology and Health Services Research VI:
Lupus/Vasculitis
Disclosure: Nothing to Disclose
Cox, Talitha, MA, OTR/L
ARHP Rehabilitation Science
Disclosure: Nothing to Disclose
Cronstein, Bruce N., MD
Cell-cell Interactions and Adhesion
Disclosure: Canfite Pharma, Bristol-Myers
Squibb, Tap Pharmaceuticals, Prometheus
Laboratories, Cypress Laboratories, Protalex,
Allos, Inc, Gismo Therapeutics, Regeneration
(Westat, DSMB), Novartis, Endocyte, Savient,
5; Canfite Piophamaceuticals, 1; Eli Lilly & Co,
9; UCB, 9; Pfizer, 9; Vilcek Foundation; 6; King
Pharmaceuticals; NIH; Vilcek Foundation; OSI
Pharmaceuticals; Gilead Pharmaceuticals; URL
Pharma, 2
Curtis, Jeffrey R., MD, MPH, MSPH
Epidemiology and Health Services Research V:
Drugs
Disclosure: Amgen, 2; Centocor, Inc, 2, 5;
Corrona, 2, 5; Roche Pharmaceuticals, 2, 5, 8;
UCB, 5, 8
Cush, John J., MD
Rheumatoid Arthritis Treatment - Small
Molecules, Biologics, Therapy: Further Insights
Into Efficacy and Safety of Tumor Necrosis
Factor-Inhibitors
Disclosure: Abbott Immunology
Pharmaceuticals, 5; Allos, 5; Amgen, 5; Auxilum,
5; Celgene, 5; Cellestis, 5; Centorcor, 5; Flexion,
5; Genentech and Biogen IDEC Inc, 5; Human
Genome Sen, 5; Ortho Biotech Products L.P., 5;
Pfizer Inc, 5; UCB, 2, 4
de Vallejo, Abbe N., PhD
Pediatric Rheumatology - Pathogenesis
Disclosure: Nothing to Disclose
Del Galdo, Francesco, MD, PhD
Systemic Sclerosis Fibrosing Syndromes and
Raynaud’s - Pathogenesis, Animal Models and
Genetics II
Disclosure: Nothing to Disclose
Del Rincon, Inmaculada, MD, MSc
Rheumatoid Arthritis Clinical Aspects:
Cardiovascular Disease
Disclosure: Nothing to Disclose
Dellaripa, Paul F., MD
Rheumatoid Arthritis Clinical Aspects: Clinical
Features
Disclosure: BIogen, 9
D
396
2011 Program Book